Arturo Molina

Abiraterone in metastatic prostate cancer without previous chemotherapy.

F. Saad, E. Basch, J. Carles, 2013, The New England journal of medicine.

Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer

H. Scher, P. Mulders, T. Flaig, 2013, Prostate Cancer and Prostatic Disease.

Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.

H. Scher, M. Stöckle, D. Rathkopf, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer

A. Tolcher, B. Kaiser, A. Patnaik, 2012, Cancer Chemotherapy and Pharmacology.

Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): Impact of prior ketoconazole (keto).

H. Scher, G. Bubley, D. Danila, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302

D. Cella, S. Traina, N. Shore, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.